Treatment of onychomycosis in diabetic patients

Clinical Diabetes

Volumn 24, Issue 4, 2006, Pages 160-166

  Winston, Jason A ^a   Miller, Jami L ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CLOTRIMAZOLE; DIGOXIN; ERYTHROMYCIN; FLUCONAZOLE; GLIBENCLAMIDE; GLIPIZIDE; GRISEOFULVIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROTON PUMP INHIBITOR; TERBINAFINE; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DOSE RESPONSE; DRUG POTENTIATION; DYSPEPSIA; FLATULENCE; FUNGUS CULTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LICHEN PLANUS; NAUSEA; ONYCHOMYCOSIS; PATHOGENESIS; PHYSICAL EXAMINATION; PSORIASIS; RASH; REVIEW; RHINITIS; SINUSITIS; TASTE DISORDER; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING;

EID: 33750628491     PISSN: 08918929     EISSN: 08918929     Source Type: Journal    
DOI: 10.2337/diaclin.24.4.160     Document Type: Review

References (62)

1. National Institute of Diabetes and Digestive and Kidney Diseases: National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, Md., U.S. Department of Health and Human Services, National Institutes of Health, 2005
2. Faergemann J, Baran R: Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermato 149 (Suppl.):1-4, 2003
3. Rich P, Hare A: Onychomycosis in a special patient population: focus on the diabetic. Int J Dermatol 38 (Suppl. 2):17-19, 1999
4. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, McManus R, Summerbell RC: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 139:665-671, 1998
5. Pierard GE, Pierard-Franchimont C: The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 48:339-342, 2005
6. Lugo-Somolinos A, Sanchez JL: Prevalence of dermatophytosis in patients with diabetes. J Am Acad Dermatol 26:408-410, 1992
7. Alteras I, Saryt E: Prevalence of pathogenic fungi in the toe-webs and toe-nails of diabetic patients. Mycopathologia 67:157-159, 1979
8. Romano C, Massai L, Asta F, Signorini AM: Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 44:83-86, 2001
9. Dogra S, Kumar B, Bhansali A, Chakrabarty A: Epidemiology of onychomycosis in patients with diabetes mellitus in India. Int J Dermatol 41:647-651, 2002
10. Bokyo WL, Doyle JJ, Ryu S, Gause D: Onychomycosis and its impact on secondary infection development in the diabetic population. Presentation at the 4th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Va., 1999
11. Levy LA: Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 87:546-550, 1997
12. Scher RK: Onychomycosis: a significant medical disorder. J Am Acad Dermatol 35:S2-S5, 1996
13. Gupta AK, Humke S: The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 10:379-384, 2000
14. Rich P: Onychomycosis and tinea pedis in patients with diabetes. J Am Acad Dermatol 43 (5 Suppl.):S130-S134, 2000
15. Rich P: Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol 35:S10-S12, 1996
16. Martin ES, Elewski BE: Cutaneous fungal infections in the elderly. Clin Geriatr Med 18:59-75, 2002
17. Agency for Healthcare Research and Quality: HCUPnet, Healthcare Cost and Utilization Project. Rockville, Md., Agency for Healthcare Research and Quality, 2000
18. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA: The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26:1790-1795, 2003
19. Reiber GE, Boyko EJ, Smith DG: Lower extremity foot ulcers and amputation in diabetes. In Diabetes in America. Bethesda, Md., National Diabetes Data Group, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995
20. Tom CM, Kane MP: Management of toenail onychomycosis. Am J Health Syst Pharm 56:865-871, 1999
21. Lateur N, Mortaki A, Andre J: Two hundred ninety-six cases of onychomycosis in children and teenagers: a 10-year laboratory survey. Pediatr Dermatol 20:385-388, 2003
22. Kemna ME, Elewski BE: A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 35:539-542, 1996
23. Hay RJ, Baran R, Haneke E: Fungal (onychomycosis) and other infections involving the nail apparatus. In Diseases of the Nails and their Management. Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, Eds. Malden, Mass. Blackwell Science, 2001
24. Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 11:415-429, 1998
25. Mahoney JM, Bennet J, Olsen B: The diagnosis of onychomycosis. Dermatol Clin 21:463-467, 2003
26. Jaffe R: Onychomycosis: recognition, diagnosis, and management. Arch Fam Med 7:587-592, 1998
27. Mayeaux EJ Jr: Nail disorders. Prim Care 27:333-351, 2000
28. Singh G, Haneef NS, Uday A: Nail changes and disorders among the elderly. Indian J Dermatol Venereol Leprol 71:386-392, 2005
29. Baran R, Badillet G: Primary onycholysis of the big toenails: a review of 113 cases. Br J Dermatol 106:529-534, 1982
30. Lawry MA, Haneke E, Strobeck K, Martin S, Zimmer B, Romano PS: Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 136:1112-1116, 2000
31. Rich P, Harkless LB, Atillasoy ES: Dermatophyte test medium culture for evaluating toenail infections in patients with diabetes. Diabetes Care 26:1480-1484, 2003
32. Lawry MA, Haneke E, Strobeck K, Martin S, Zimmer B, Romano PS: Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 136:1112-1116, 2000
33. Mehregan DR, Gee SL: The cost effectiveness of testing for onychomycosis versus empiric treatment of onychodystrophies with oral antifungal agents. Cutis 64:407-410, 1999
34. Weinberg JM, Koestenblatt EK, Tutrone WD, Tishler HR, Najarian L: Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 49:193-197, 2003
35. Gupta AK, Fleckman P, Baran R: Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 43 (4 Suppl.):S70-S80, 2000
36. Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G: Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 146:254-260, 2002
37. Zisova LG: Fluconazole in the treatment of onychomycosis. Folia Med 46:47-50, 2004
38. Willemsen M, De Doncker P, Willems J, Woestenborghs R, Van de Velde V, Heykants J, Van Cutsem J, Cauwenbergh G, Roseeuw D: Posttreatment itraconazole levels in the nail: new implications for treatment in onychomycosis. J Am Acad Dermatol 26:731-735, 1992
39. Gupta AK, De Doncker P, Scher RK, Haneke E, Daniel CR 3rd, Andre J, Baran R: Itraconazole for the treatment of onychomycosis. Int J Dermatol 37:303-308, 1998
40. Albreski DA, Gross EG: The safety of itraconazole in the diabetic population. J Am Podiatr Med Assoc 89:339-345, 1999
41. Verspeelt J, Marynissen G, Gupta AK, De Doncker P: Safety of itraconazole in diabetic patients. Dermatology 198:382-384, 1999
42. Goodfield MJ: Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 126 (Suppl. 39):33-35, 1992
43. Bohannon NK, Streja L: Effectiveness of terbinafine therapy for toenail onychomycosis in persons with diabetes (Abstract). Diabetes 49 (Suppl. 1):A195, 2000
44. Warshaw EM, Fett DD, Bloomfield HE, Grill JP, Nelson DB, Quintero V, Carver SM, Zielke GR, Lederle FA: Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 53:578-584, 2005
45. Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, Bakshi R: Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat 17:38-44, 2006
46. Cribier BJ, Bakshi R: Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatol 150:414-420, 2004
47. Pollak R, Billstein SA: Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc 87:565-570, 1997
48. De Backer M, De Keyser P, De Vroey C, Lesaffre E: A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day - a double-blind comparative trial. Br J Dermatol 134 (Suppl. 46):16-17, 1996.
49. [Discussion Br J Dermatol 134 (Suppl. 46):38, 1996]
50. Gupta AK, Konnikov N, Lynde CW: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 44:479-484, 2001
51. Evans EG, Sigurgeirsson B: Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 318:1031-1035, 1999
52. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138:353-357, 2002
53. Gupta AK, Shear NH: A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 22:33-52, 2000
54. Terbinafine package insert. East Hanover, N.J., Novartis Pharmaceuticals, 2005
55. Itraconazole package insert. Titusville, N.J., Janssen Pharmaceutical Products, 2004
56. Bootman JL: Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 38:S69-S72, 1998
57. Baran R: Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 145 (Suppl. 60):15-19, 2001
58. Lecha M: Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 145 (Suppl. 60):21-26, 2001
59. Gupta AK, Onychomycosis Combination Therapy Study Group: Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 4:481-485, 2005
60. Avner S, Nir N, Henri T: Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 16:327-330, 2005
61. Robbins JM: Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications 17:98-104, 2003
62. Del Rosso JQ: Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 97:339-346, 1997